Cross-talk between the proto-oncogenes Met and Ron
- PMID: 10871856
- DOI: 10.1038/sj.onc.1203620
Cross-talk between the proto-oncogenes Met and Ron
Abstract
Scatter Factors control a complex genetic program known as 'invasive growth'. HGF (Scatter factor 1) and MSP (Scatter Factor 2) bind to tyrosine kinase receptors encoded by the proto-oncogenes MET and RON. Using the appropriate 'kinase inactive' mutant receptors, we show that ligand-induced activation of Met results in transphosphorylation of Ron, and vice versa. Transphosphorylation is direct, as it occurs in Met or Ron receptors lacking the docking sites for signal transducers. Phosphate groups are transferred to the tyrosine phosphorylation sites responsible both for kinase up-regulation (Met: Y1234/Y1235 and Ron: Y1238/Y1239) and for generation of signal transducer docking sites (Met: Y1349/Y1356 and Ron Y1353/Y1360). The transphosphorylation specifically takes place for the receptor subfamily, as it is not observed between Met or Ron and ErbB1, ErbB2 or TrkA. Cross-linking experiments show that non-covalent Met-Ron complexes are present on the cell surface, before ligand-induced dimerization. Co-expression of a kinase inactive Ron receptor with naturally-occurring oncogenic Met mutants suppresses the transforming phenotype, suggesting a dominant negative role for the inefficient kinase partner. These data show that, while specific for their ligands, scatter factor receptors cross-talk and cooperate in intracellular signaling.
Similar articles
-
MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.J Cell Physiol. 1999 Dec;181(3):507-14. doi: 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q. J Cell Physiol. 1999. PMID: 10528237
-
Ron kinase transphosphorylation sustains MET oncogene addiction.Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6. Cancer Res. 2011. PMID: 21212418
-
Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway.Mol Cell Biol. 2001 Sep;21(17):5857-68. doi: 10.1128/MCB.21.17.5857-5868.2001. Mol Cell Biol. 2001. PMID: 11486025 Free PMC article.
-
Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.Histol Histopathol. 2001 Apr;16(2):623-31. doi: 10.14670/HH-16.623. Histol Histopathol. 2001. PMID: 11332718 Review.
-
Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.EXS. 1993;65:131-65. EXS. 1993. PMID: 8380735 Review.
Cited by
-
Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.PLoS One. 2012;7(7):e41912. doi: 10.1371/journal.pone.0041912. Epub 2012 Jul 25. PLoS One. 2012. PMID: 22848655 Free PMC article.
-
The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.Oncogene. 2014 Mar 13;33(11):1429-37. doi: 10.1038/onc.2013.84. Epub 2013 Apr 1. Oncogene. 2014. PMID: 23542172 Free PMC article.
-
The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.Cancers (Basel). 2022 Apr 18;14(8):2037. doi: 10.3390/cancers14082037. Cancers (Basel). 2022. PMID: 35454943 Free PMC article. Review.
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.Cancer Biol Ther. 2011 Jul 1;12(1):9-46. doi: 10.4161/cbt.12.1.15747. Epub 2011 Jul 1. Cancer Biol Ther. 2011. PMID: 21543897 Free PMC article.
-
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer.Exp Mol Med. 2016 Dec 16;48(12):e279. doi: 10.1038/emm.2016.114. Exp Mol Med. 2016. PMID: 27980342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous